Breast cancers that express high levels of Endo180 receptor (Mrc2) mRNA, which is expressed in myCAFs, are less sensitive to anti-PD-L1 and anti-CTLA4 ICIs in murine models and in human BC tissues. This evidence concerns the gene CTLA4 and breast cancer.